Howard Chan
YOU?
Author Swipe
View article: Supplemental Table 5 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes
Supplemental Table 5 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes Open
Protein-protein network analysis
View article: Supplemental Table 4 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes
Supplemental Table 4 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes Open
Tyrosine phosphorylation dataset derived from the sarcoma panel
View article: Data from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes
Data from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes Open
Despite intensive multimodal treatment of sarcomas, a heterogeneous group of malignant tumors arising from connective tissue, survival remains poor. Candidate-based targeted treatments have demonstrated limited clinical success, urging an …
View article: Supplemental Table 4 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes
Supplemental Table 4 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes Open
Tyrosine phosphorylation dataset derived from the sarcoma panel
View article: Supplemental Table 5 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes
Supplemental Table 5 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes Open
Protein-protein network analysis
View article: Data from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes
Data from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes Open
Despite intensive multimodal treatment of sarcomas, a heterogeneous group of malignant tumors arising from connective tissue, survival remains poor. Candidate-based targeted treatments have demonstrated limited clinical success, urging an …
View article: Supplementary Tables 1-3 and Figures 1-9 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes
Supplementary Tables 1-3 and Figures 1-9 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes Open
This file contains the following supplemental data: Supplemental Table 1. Specific information for MTT cell viability assays with single agents. Supplemental Table 2. Patient characteristics of synovial sarcoma cohort. Supplemental Table 3…
View article: Supplementary Tables 1-3 and Figures 1-9 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes
Supplementary Tables 1-3 and Figures 1-9 from Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes Open
This file contains the following supplemental data: Supplemental Table 1. Specific information for MTT cell viability assays with single agents. Supplemental Table 2. Patient characteristics of synovial sarcoma cohort. Supplemental Table 3…
View article: Supplementary Figures from Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway
Supplementary Figures from Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway Open
Supplementary Figures PDF file - 1342K, Supplementary Figures for Croucher et al. Supplementary Figure 1: SILAC-based (phospho)-proteomic analysis in basal breast cancer cell lines following Lyn knockdown. Supplementary Figure 2: Lyn regul…
View article: Supplementary Figures from Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway
Supplementary Figures from Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway Open
Supplementary Figures PDF file - 1342K, Supplementary Figures for Croucher et al. Supplementary Figure 1: SILAC-based (phospho)-proteomic analysis in basal breast cancer cell lines following Lyn knockdown. Supplementary Figure 2: Lyn regul…
View article: Data from Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway
Data from Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway Open
Basal breast cancer cells feature high expression of the Src family kinase Lyn that has been implicated in the pathogenicity of this disease. In this study, we identified novel Lyn kinase substrates, the most prominent of which was the aty…
View article: Data from Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway
Data from Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway Open
Basal breast cancer cells feature high expression of the Src family kinase Lyn that has been implicated in the pathogenicity of this disease. In this study, we identified novel Lyn kinase substrates, the most prominent of which was the aty…
View article: INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG) Open
Background Advanced gastro-oesophageal cancer (AGOC) carries a poor prognosis. No standard of care treatment options are available after first and second-line therapies. Regorafenib is an oral multi-targeted tyrosine kinase inhibitor targe…
View article: Additional file 3 of FGFR3 signaling and function in triple negative breast cancer
Additional file 3 of FGFR3 signaling and function in triple negative breast cancer Open
Additional file 2: Table S1. Quantifiable FGFR tyrosine phosphorylated peptide expression (log2) identified across 24 TNBC cell lines Table S2. Quantifiable tyrosine phosphorylated peptide expression (log2) specific to SUM185PE cell line. …
View article: Additional file 3 of FGFR3 signaling and function in triple negative breast cancer
Additional file 3 of FGFR3 signaling and function in triple negative breast cancer Open
Additional file 2: Table S1. Quantifiable FGFR tyrosine phosphorylated peptide expression (log2) identified across 24 TNBC cell lines Table S2. Quantifiable tyrosine phosphorylated peptide expression (log2) specific to SUM185PE cell line. …
View article: Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment
Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment Open
In prostate cancer, cancer-associated fibroblasts (CAF) exhibit contrasting biological properties to non-malignant prostate fibroblasts (NPF) and promote tumorigenesis. Resolving intercellular signaling pathways between CAF and prostate tu…
View article: Characterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation
Characterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation Open
Despite significant progress, our understanding of how specific oncogenes transform cells is still limited and likely underestimates the complexity of downstream signalling events. To address this gap, we use mass spectrometry-based chemic…
View article: Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes
Phosphoproteomic Profiling Reveals ALK and MET as Novel Actionable Targets across Synovial Sarcoma Subtypes Open
Despite intensive multimodal treatment of sarcomas, a heterogeneous group of malignant tumors arising from connective tissue, survival remains poor. Candidate-based targeted treatments have demonstrated limited clinical success, urging an …
View article: Market Structure and its Effects on the Pricing of Derivative Securities in Australia
Market Structure and its Effects on the Pricing of Derivative Securities in Australia Open
This paper examines whether two securities that have identical payoffs, the equity warrant and the exchange traded option, are priced differently when they are subject to different microstructure issues. The results show that different tra…